DATATRAK Reports Record Setting Results in 2013

Transformational Benefits of DATATRAK ONE® Drive Double Digit Sales Growth

PR Newswire

CLEVELAND, March 12, 2014 /PRNewswire/ -- DATATRAK International, Inc. (DTRK), the leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced its operating results for the calendar year and fourth quarter 2013.

"2013 was a record setting year for DATATRAK.  Industry leaders are responding very favorably to the benefits of our products: Delivering truly optimized data management solutions for clinical trials," said Laurence P. Birch, Chairman of the Board and CEO, DATATRAK.

"DATATRAK continues to anticipate the needs of the eClinical industry, actively reducing the required investment of both time and cost in the data management process, while increasing the quality of the information," Birch continued.  "Clients are experiencing the power of our transformational product suite, DATATRAK ONE®, which empowers responsive work flows, enhanced processing speed, user configurable study home page reporting, and an enriched intuitive user interface, among other benefits.  DATATRAK anticipated the need for optimization in the industry and is delivering that benefit."

"Our truly unified eClinical® solutions deliver an increase in productivity for the trial management team.  The full suite of DATATRAK solutions are built to work together, from the first line of code, accessing a single database, and delivering real-time insight through the Cloud.  Our competitive pricing reflects our purpose built solutions that require minimal maintenance, unlike some of our competitors."

"Demand for the high quality and functionality of our solutions and services has resulted in Q4 Income from Operations and the highest cash balance since 2008.  In 2014 we plan to take advantage of this momentum and accelerate investments in Sales, Marketing, R&D, and Services to drive continued new contract growth," concluded Mr. Birch.

Highlights include:

Financial Highlights:

Revenue increased by 3% to $2.85 million in the fourth quarter of 2013 compared to the same period in 2012 due to strong new contract sales which fueled backlog increases throughout 2012 and 2013. Gross profit margin remained stable at 83% for the three months ended December 31, 2013 compared to 84% for the three months ended December 31, 2012. The Company's income from operations for the three months ended December 31, 2013 was $183,000 compared to a loss from operations of $(100,000) for the corresponding period in the prior year. Quarter-over-quarter costs decreased 10%.  The decrease in costs helped boost the year-end cash balance to $3.3 million, 6% higher than the December 31, 2012 cash balance of $3.1 million.

DATATRAK's backlog at December 31, 2013 was $20.8 million compared to a backlog of $17.8 million at December 31, 2012. Backlog consists of future value from authorization letters to commence services, statements of work, technology and services agreements, change orders and other customer contracts, billed and unbilled. The improvement in backlog from December 31, 2012 to December 31, 2013 was due to new contract sales, change orders and contract amendments. 

Join DATATRAK Thought Leaders:

Tweet: #DATATRAK reports record setting 2013 with double digit Revenue Growth from demand for transformational #tech platform http://bit.ly/1oN4QdB

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.com.

All contracts are subject to possible delays or cancellation or can change in scope in a positive or negative direction. Therefore, current backlog is not necessarily indicative of the Company's future quarterly or annual revenue. Historically, backlog has been a poor predictor of the Company's short-term revenue.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements
are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on November 13, 2013 announcing its results for the third quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


DATATRAK International, Inc. and Subsidiaries
Condensed Consolidated Balance Sheet Data
(Unaudited)



December 31, 2013

December 31, 2012

Cash and cash equivalents

$3,305,852

$3,122,905

Accounts receivable, net

1,084,377

1,452,174

Property & equipment, net

190,799

93,797

Deferred tax assets

2,900

Other

461,196

410,221

   Total assets

$5,042,224

$5,081,997




Accounts payable and other current liabilities

$1,855,061

$2,342,226

Deferred revenue

4,425,167

4,642,871

Deferred tax liabilities

2,900

Other long-term liabilities

29,775

12,126

Shareholders'  deficit

(1,267,779)

(1,918,126)

   Total liabilities and shareholders' deficit

$5,042.224

$5,081,997




 

DATATRAK International, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)



For the 3 Months Ended December 31,


2013

2012

Revenue

$2,848,013

$2,776,589

Direct costs

491,109

440,418

   Gross profit

2,356,904

2,336,171




Selling, general and administrative expenses

2,162,593

2,396,073

Depreciation and amortization

11,102

39,938

   Income (loss) from operations

183,209

(99,840)




Interest income

3,715

129

Interest expense

(1,709)

(1,460)

   Net income (loss)

$ 185,215

$(101,171)

     Net income (loss) per share:



          Net income (loss) per share, basic

$       0.14

$      (0.08)

          Weighted-average shares outstanding, basic

1,364,028

1,281,444

          Net income (loss) per share, diluted

$       0.13

$      (0.08)

          Weighted-average shares outstanding, diluted

1,477,428

1,281,444

 


For the 12 Months Ended December 31,


2013

2012

Revenue

$10,900,711

$9,716,225

Direct costs

2,006,564

1,647,150

   Gross profit

8,894,147

8,069,075




Selling, general and administrative expenses

9,707,633

9,441,686

Depreciation and amortization

59,891

156,598

   Loss from operations

(873,377)

(1,529,209)




Interest income

3,955

539

Interest expense

(9,480)

(10,678)

Other income

750,000

   Net loss

$ (128,902)

$(1,539,348)

     Net loss per share:



          Net loss per share, basic

$       (0.10)

$         (1.22)

          Weighted-average shares outstanding, basic

1,345,955

1,265,467

          Net loss per share, diluted

$       (0.10)

$        (1.22)

          Weighted-average shares outstanding, diluted

1,345,955

1,265,467

 

Rates

View Comments (0)